Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing. (16th October 2020)

• Record Type: Journal Article
• Authors: Jahrsdörfer, Bernd; Kroschel, Joris; Ludwig, Carolin; Corman, Victor Max; Schwarz, Tatjana; Körper, Sixten; Rojewski, Markus; Lotfi, Ramin; Weinstock, Christof; Drosten, Christian; Seifried, Erhard; Stamminger, Thomas; Groß, Hans Jürgen; Schrezenmeier, Hubert
• Is Part Of: Journal of infectious diseases. Volume 223:Number 5(2021)
• Page Start: 796
• Page End: 801
• Publication Date: 2020-10-16
• Subjects: SARS-CoV-2 -- ELISA -- CLIA -- ECLIA -- CMIA -- neutralization test -- spike -- nucleocapsid; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiaa656
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Highly sensitive and specific platforms for the detection of anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies are becoming increasingly important for evaluating potential SARS-CoV-2 convalescent plasma donors, studying the spread of SARS-CoV-2 infections, and identifying individuals with seroconversion. This study provides a comparative validation of 4 anti–SARS-CoV-2 platforms. A unique feature of the study is the use of a representative cohort of convalescent patients with coronavirus disease 2019 and a mild to moderate disease course. All platforms showed significant correlations with a SARS-CoV-2 plaque reduction neutralization test, with highest sensitivities for the Euroimmun and the Roche platforms, suggesting their preferential use for screening persons at increased risk of SARS-CoV-2 infections. Abstract : Four broadly used serological testing platforms for detecting antibodies against severe acute respiratory syndrome coronavirus 2 were evaluated regarding their suitability for screening healthcare staff, potential convalescent plasma donors, and others with mild to moderate courses of coronavirus disease 2019.